AIMS: The aim of this study was to determine the predictive role of pretreatment carbohydrate antigen 19-9 (CA19-9) measurement and its change after one cycle of gemcitabine-based therapy for response, time to progression (TTP) and overall survival (OS). METHODS: Analyses were derived from three consecutive gemcitabine-containing phase II clinical trials between 1997 and 2004. RESULTS: A total of 111 patients with pancreas cancer was studied. Baseline CA19-9 concentrations were dichotomized near the median. Lower baseline CA19-9 levels were positively associated with OS (median 9.1 vs 6.1 months, P = 0.0057) and TTP (median 6.4 vs 4.2 months, P = 0.0044).The covariate adjusted hazard ratio (HR) for progression among patients with baseline CA19-9 >or= 1000 ng/mL was HR = 1.94 (95% CI 1.24-3.02), with P = 0.0035. The covariate adjusted risk of death among patients with baseline CA19-9 >or= 1000 ng/ml was similarly elevated: HR = 1.90 (95% CI 1.23-2.94), with P = 0.0039. Change in CA19-9 levels from baseline to the end of treatment cycle 1 did not predict objective response (P = 0.75). There was somewhat longer OS (median 8.7 vs 7.1 months) and TTP (median 7.1 vs 5.4 months) in patients with >or=50% reduction in serum CA19-9 concentrations, but this was not statistically significant (P = 0.74 and 0.81, respectively). CONCLUSION: Baseline CA19-9 levels may predict survival in patients with advanced pancreas cancer. The change in CA19-9 levels determined within 1 month of the initiation of therapy did not predict treatment outcome.
AIMS: The aim of this study was to determine the predictive role of pretreatment carbohydrate antigen 19-9 (CA19-9) measurement and its change after one cycle of gemcitabine-based therapy for response, time to progression (TTP) and overall survival (OS). METHODS: Analyses were derived from three consecutive gemcitabine-containing phase II clinical trials between 1997 and 2004. RESULTS: A total of 111 patients with pancreas cancer was studied. Baseline CA19-9 concentrations were dichotomized near the median. Lower baseline CA19-9 levels were positively associated with OS (median 9.1 vs 6.1 months, P = 0.0057) and TTP (median 6.4 vs 4.2 months, P = 0.0044).The covariate adjusted hazard ratio (HR) for progression among patients with baseline CA19-9 >or= 1000 ng/mL was HR = 1.94 (95% CI 1.24-3.02), with P = 0.0035. The covariate adjusted risk of death among patients with baseline CA19-9 >or= 1000 ng/ml was similarly elevated: HR = 1.90 (95% CI 1.23-2.94), with P = 0.0039. Change in CA19-9 levels from baseline to the end of treatment cycle 1 did not predict objective response (P = 0.75). There was somewhat longer OS (median 8.7 vs 7.1 months) and TTP (median 7.1 vs 5.4 months) in patients with >or=50% reduction in serum CA19-9 concentrations, but this was not statistically significant (P = 0.74 and 0.81, respectively). CONCLUSION: Baseline CA19-9 levels may predict survival in patients with advanced pancreas cancer. The change in CA19-9 levels determined within 1 month of the initiation of therapy did not predict treatment outcome.
Authors: Everardo D Saad; Marcel C Machado; Dalia Wajsbrot; Roberto Abramoff; Paulo M Hoff; Jacques Tabacof; Artur Katz; Sergio D Simon; René C Gansl Journal: Int J Gastrointest Cancer Date: 2002
Authors: Gershon Y Locker; Stanley Hamilton; Jules Harris; John M Jessup; Nancy Kemeny; John S Macdonald; Mark R Somerfield; Daniel F Hayes; Robert C Bast Journal: J Clin Oncol Date: 2006-10-23 Impact factor: 44.544
Authors: Caio Max S Rocha Lima; Diane Savarese; Howard Bruckner; Arkadiusz Dudek; John Eckardt; John Hainsworth; Furhan Yunus; Eric Lester; William Miller; Wayne Saville; Gary L Elfring; Paula K Locker; Linda D Compton; Langdon L Miller; Mark R Green Journal: J Clin Oncol Date: 2002-03-01 Impact factor: 44.544
Authors: B F El-Rayes; M M Zalupski; A F Shields; U Vaishampayan; L K Heilbrun; V Jain; V Adsay; J Day; P A Philip Journal: J Clin Oncol Date: 2003-08-01 Impact factor: 44.544
Authors: J Stemmler; P Stieber; A M Szymala; A Schalhorn; M M Schermuly; R Wilkowski; T Helmberger; R Lamerz; C Stoffregen; K Niebler; M Garbrecht; V Heinemann Journal: Onkologie Date: 2003-10
Authors: C Ziske; C Schlie; M Gorschlüter; A Glasmacher; U Mey; J Strehl; T Sauerbruch; I G H Schmidt-Wolf Journal: Br J Cancer Date: 2003-10-20 Impact factor: 7.640
Authors: Brian A Boone; Nathan Bahary; Amer H Zureikat; A James Moser; Daniel P Normolle; Wen-Chi Wu; Aatur D Singhi; Phillip Bao; David L Bartlett; Lance A Liotta; Virginia Espina; Patricia Loughran; Michael T Lotze; Herbert J Zeh Journal: Ann Surg Oncol Date: 2015-04-24 Impact factor: 5.344
Authors: Khanh T Nguyen; Aparna Kalyan; H Scott Beasley; Aatur D Singhi; Weijing Sun; Herbert J Zeh; Daniel Normolle; Nathan Bahary Journal: J Gastrointest Oncol Date: 2017-06
Authors: Todd M Bauer; Bassel F El-Rayes; Xiaobai Li; Nazik Hammad; Philip A Philip; Anthony F Shields; Mark M Zalupski; Tanios Bekaii-Saab Journal: Cancer Date: 2012-07-11 Impact factor: 6.860
Authors: Mohamed A Khalil; Wei Qiao; Peter Carlson; Binsah George; Milind Javle; Michael Overman; Gauri Varadhachary; Robert A Wolff; James L Abbruzzese; David R Fogelman Journal: Invest New Drugs Date: 2013-05-04 Impact factor: 3.850